These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1802149)

  • 1. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents.
    Hoener B; Engelstad BL; Ramos EC; Macapinlac HA; Price DC; Johnson TR; White DL
    J Magn Reson Imaging; 1991; 1(3):357-62. PubMed ID: 1802149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fe(III)-EHPG and Fe(III)-5-Br-EHPG as contrast agents in MRI: an animal study.
    Liu GC; Wang YM; Jaw TS; Chen HM; Sheu RS
    J Formos Med Assoc; 1993 Apr; 92(4):359-66. PubMed ID: 8104585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
    Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
    J Comput Assist Tomogr; 1985; 9(3):431-8. PubMed ID: 3989032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential radiopharmaceuticals for the diagnosis of biliary atresia and neonatal hepatitis: EHPG and HBED chelates of 67Ga and 111In.
    Hunt FC
    Int J Rad Appl Instrum B; 1988; 15(6):659-64. PubMed ID: 3150845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
    Hershko C; Grady RW; Link G
    Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives.
    Lauffer RB; Vincent AC; Padmanabhan S; Villringer A; Saini S; Elmaleh DR; Brady TJ
    Magn Reson Med; 1987 Jun; 4(6):582-90. PubMed ID: 3613958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of Fe-(5-C2H5-EHPG)- as a contrast agent in MR imaging of hepatobiliary system.
    Sheu RS; Liu GC; Wang YM; Jaw TS; Chen HM; Kuo YT
    Kaohsiung J Med Sci; 1997 Feb; 13(2):75-85. PubMed ID: 9099045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UV and fluorescence spectral changes induced by neodymium binding of N,N'-ethylenebis[2-(o-hydroxyphenolic)glycine] and N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N' diacetic acid.
    Wang Z; Yang B
    Spectrochim Acta A Mol Biomol Spectrosc; 2006 Nov; 65(3-4):946-9. PubMed ID: 16684618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenolic aminocarboxylate chelates of 99mTc as hepatobiliary agents.
    Hunt FC; Maddalena DJ; Wilson JG; Bautovich GJ
    Int J Rad Appl Instrum B; 1986; 13(3):289-93. PubMed ID: 3095271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fe-HBED Analogs: A Promising Class of Iron-Chelate Contrast Agents for Magnetic Resonance Imaging.
    Bales BC; Grimmond B; Johnson BF; Luttrell MT; Meyer DE; Polyanskaya T; Rishel MJ; Roberts J
    Contrast Media Mol Imaging; 2019; 2019():8356931. PubMed ID: 31969797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.
    Hershko C; Grady RW; Link G
    J Lab Clin Med; 1984 Mar; 103(3):337-46. PubMed ID: 6699459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferrioxamine B derivatives as hepatobiliary contrast agents for magnetic resonance imaging.
    Muetterties KA; Hoener BA; Engelstad BL; Tongol JM; Wikstrom MG; Wang SC; Eason RG; Moseley ME; White DL
    Magn Reson Med; 1991 Nov; 22(1):88-100. PubMed ID: 1798398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic transport of the magnetic resonance imaging contrast agent Fe(III)-N-(3-phenylglutaryl)desferrioxamine B.
    Hoener BA; Tzika AA; Englestad BL; White DL
    Magn Reson Med; 1991 Feb; 17(2):509-15. PubMed ID: 1905776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of physicochemical and in-vivo behavior of diastereomeric iron-59, gallium-68, and indium-111-EHPG trivalent metal complexes.
    Madsen SL; Bannochie CJ; Martell AE; Mathias CJ; Welch MJ
    J Nucl Med; 1990 Oct; 31(10):1662-8. PubMed ID: 2213190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH; Cerny EA; Wright BJ; Rahman YE
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
    Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
    Int J Rad Appl Instrum B; 1988; 15(1):47-9. PubMed ID: 3350696
    [No Abstract]   [Full Text] [Related]  

  • 17. EHPG iron(III) complexes as potential contrast contrast agents for MRI.
    Kuźnik N; Jewuła P; Oczek L; Kozłowicz S; Grucela A; Domagała W
    Acta Chim Slov; 2014; 61(1):87-93. PubMed ID: 24664331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
    Hershko C; Grady RW; Link G
    Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimalarial effect of HBED and other phenolic and catecholic iron chelators.
    Yinnon AM; Theanacho EN; Grady RW; Spira DT; Hershko C
    Blood; 1989 Nov; 74(6):2166-71. PubMed ID: 2508794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectral studies on the interaction of yttrium ion with the ligands of phenolic groups: N,N'-Ethylenebis[2-(o-hydroxyphenolic)glycine] and N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid.
    Duan L; Zhao YQ; Yang BS
    Spectrochim Acta A Mol Biomol Spectrosc; 2007 Sep; 68(1):165-8. PubMed ID: 17267267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.